|
|
Publications since 2002 |
1. Peterson, G.M., Practical utility of case-management telephone intervention in heart failure? Arch Intern Med, 2002. 162 (18): p. 2142-3; author reply 2143.
2. Peterson, G.M., Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis. Obstet Gynecol, 2002. 100 (2): p. 381; author reply 381-2.
3. Peterson, G.M., et al., Doctors' beliefs on the use of antithrombotic therapy in atrial fibrillation: identifying barriers to stroke prevention. Intern Med J, 2002. 32 (1-2): p. 15-23.
4. Peterson GM and Jackson SL, Reducing the hazards of anticoagulation in elderly patients through near-patient testing by pharmacists. Aust Pharmacist, 2002. 21 (9): p. 679-681.
6. Peterson, G.M. and S.L. Jackson, Cost-effectiveness of newer antiplatelet drugs. Arch Intern Med, 2003. 163 (20): p. 2533-4; author reply 2534.
7. Peterson, G.M., et al., Ipratropium treatment of acute airways disease. Ann Pharmacother, 2003. 37 (3): p. 339-44.
8. Peterson GM, Jackson SL, and Naunton M, Communication problems in the elderly can lead to disasters: chaos theory in action. Aust Pharmacist, 2003. 22 (1): p. 49-51.
9. Peterson GM, Naunton M, and Fitzmaurice KD, Should the elderly take multivitamins? Australian Pharmacist, 2003. 22 (5): p. 49-51.
10. Peterson GM and Jackson SL, Warfarin education by community pharmacists: a crucial role to minimise adverse events and maximise benefits. Aust Pharmacist, 2003. 22 (11): p. 832-834.
11. Peterson GM, Naunton M, and Fitzmaurice KD, The drugs could be ok, but do not forget about problems with dosage forms. Australian Pharmacist, 2003. 22 (3): p. 212-215.
12. Boyles, P.J., et al., Undertreatment of congestive heart failure in an Australian setting. J Clin Pharm Ther, 2004. 29 (1): p. 15-22.
13. Featherstone AM, et al., Comparison of methods for the determination of total selenium in plasma by magnetic sector ICP-MS. Anal Chim Acta, 2004. 512 : p. 319-327.
14. Jackson, S.L., et al., Point-of-care monitoring of anticoagulant therapy by rural community pharmacists: description of successful outcomes. Aust J Rural Health, 2004. 12 (5): p. 197-200.
15. Jackson, S.L., G.M. Peterson, and J.H. Vial, A community-based educational intervention to improve antithrombotic drug use in atrial fibrillation. Ann Pharmacother, 2004. 38 (11): p. 1794-9.
16. Jackson, S.L., et al., Accuracy and clinical usefulness of the near-patient testing CoaguChek S international normalised ratio monitor in rural medical practice. Aust J Rural Health, 2004. 12 (4): p. 137-42.
17. Jackson, S.L., et al., Improving the outcomes of anticoagulation: an evaluation of home follow-up of warfarin initiation. J Intern Med, 2004. 256 (2): p. 137-44.
18. Jackson, S., et al., Suboptimal anticoagulant management in patients after hospital initiation of warfarin. Aust Fam Physician, 2004. 33 (6): p. 477-8.
19. Jackson, S.L., et al., Accuracy, reproducibility and clinical utility of the CoaguChek S portable international normalized ratio monitor in an outpatient anticoagulation clinic. Clin Lab Haematol, 2004. 26 (1): p. 49-55.
20. Jackson SL and Peterson GM, Health screening in community pharmacy. Australian Pharmacist, 2004. 23 (11): p. 760-764.
21. Jackson SL and Peterson GM, Managing atrial fibrillation: rate control or rhythm control in the elderly? Aust Pharm, 2004. 23 (235-237).
22. Jackson SL and Peterson GM, Antithrombotics . Essential CPE, ed. A. Daniels. 2004, Sydney: Pharmaceutical Society of Australia.
23. Jackson SL, M.S., Peterson GM, Bereznicki LRE, Jupe DML, Marsden KA,. A review of the initiation of anticoagulation: does lack of adherence to guidelines result in an increased risk of adverse outcomes? 2004.
24. Naunton, M., G.M. Peterson, and G. Jones, Addressing information needs in the management of osteoporosis. Osteoporos Int, 2004. 15 (6): p. 505; author reply 506.
25. Naunton, M., et al., Multifaceted educational program increases prescribing of preventive medication for corticosteroid induced osteoporosis. J Rheumatol, 2004. 31 (3): p. 550-6.
26. Peterson, G.M., Risk factors...but only after excluding high-risk subjects. Pharmacoepidemiol Drug Saf, 2004. 13 (4): p. 253; author reply 255-6.
27. Peterson, G.M. and S.L. Jackson, Randomized trial of warfarin nomograms. Ann Intern Med, 2004. 140 (6): p. 488; author reply 491-2.
28. Peterson, G.M., et al., Impact of pharmacist-conducted home visits on the outcomes of lipid-lowering drug therapy. J Clin Pharm Ther, 2004. 29 (1): p. 23-30.
29. Peterson GM, Influenza vaccination: an additional strategy to prevent heart attacks in the elderly? Aust Pharmacist, 2004. 23 : p. 395-396.
30. Peterson GM, Continuing evidence of inappropriate medication usage in the elderly. Aust Pharmacist, 2004. 23 : p. 533-535.
31. Peterson GM, Hidden dangers of complementary medicine in the elderly. Aust Pharmacist, 2004. 23 : p. 622-624.
32. Peterson GM, Reeve JF, and Vial J, MedSafety - www.medsafety.net . Aust Prescriber, 2004. 27 : p. 112-3.
33. Peterson GM and Tenni PC, Ìdentifying , prioritising and documenting drug-related problems. Aust Pharmacist, 2004. 23 : p. 706-709.
34. Peterson GM and Jackson SL, Rising costs of medications: a barrier to quality use of medicines in the elderly? Aust Pharmacist, 2004. 23 : p. 765-767.
35. Peterson GM and Jackson SL, When medication misadventure results in patient harm: too many holes in the cheese. Aust Pharmacist, 2004. 23 : p. 782-787.
36. Reeve JF, Peterson GM, and vial J. Improving medication safety in hospitals: the challenges and the initiatives . in Australasian Pharmaceutical Sciences Association Conference . 2004. Melbourne, Australia.
37. Townsend AT, et al., Elevated Selenium concentrations in Seronorm TM Trace Elements Serum. Clin Chem, 2004. 50 : p. 1481.
38. Bereznicki LR, Jackson SL, and Peterson GM, The direct thrombin inhibitor melagatran/ximelagatran. Med J Aust, 2005. 182 (5): p. 254-5.
39. Bereznicki LR, Jackson SL, and Peterson GM, Closing the gap between evidence and practice. Journal of pharmacy practice and research, 2005. 35 (3): p. 173-176.
40. Bereznicki LR, Peterson GM, and Jackson SL, Venous thromboembolism: under-use of prophylaxis for medical and nursing home patients. Australian Pharmacist, 2005. 24 (5): p. 402-404.
41. Bereznicki LR, Jackson SL, and Peterson GM, Pharmacists bridging the gap between evidence and practice. Over-use of antibiotics for acute otitis media. Aust Pharmacist, 2005. 24 : p. 798.
42. Bereznicki LR, et al. An intervention to improve adherence to an initiation protocol and improve clinical outcomes for patients commenced on warfarin. in Society of Hospital Pharmacists of Australia, Federal Conference . 2005. Brisbane, Queensland.
43. Bereznicki LR, et al. The use of thromboprophylaxis for venous thromboembolism (VTE) in hospitalised medical patients . in Society of Hospital Pharmacists of Australia, Federal Conference . 2005. Brisbane, Queensland.
44. Bereznicki LR, et al. The use of thromboprophylaxis for venous thromboembolism in hospitalised medical patients at the Royal Hobart Hospital . in Society of Hospital Pharmacists of Australia, Tasmania Branch Annual Conference . 2005. St Helens, Tasmania.
45. Bereznicki LR, et al. The use of thromboprophylaxis for venous thromboembolism (VTE) in hospitalised medical patients. in HSANZ/ANZSBT/ASTH Annual Scientific Meeting . 2005. Sydney Convention & Exhibition Centre, Australia.
46. Bereznicki LR, et al., Anticoagulation self-monitoring education program . 1 ed. Vol. 1. 2005: UMORE.
47. Bereznicki LR and Jackson SL, Point-of-Care INR monitoring in general practice . 1 ed. Vol. 1. 2005: UMORE.
48. Boland C, et al. Reducing harm associated with warfarin therapy: An national medication safety collaborative project . in Medicines Managers: The next generation . 2005. The Society of Hospital Pharmacists of Australia 27th Federal Conference, Brisbane, Queensland.
49. Boland C, et al. Reducing harm associated with warfarin therapy. A National Medication Safety Breakthrough Project . in The Society of Hospital Pharmacists of Australia, Tasmanian State Branch, 2005 Conference . 2005. St Helens, Tasmania.
50. Duyvendak M, et al., A pilot study of doctor's beliefs and knowledge on corticosteroid-induced osteoporosis prevention: identifying barriers to improve practice. Eur J Hosp Pharm, 2005. 11 : p. 114-120.
51. Jackson, S.L., et al., Improving the outcomes of anticoagulation in rural Australia: an evaluation of pharmacist-assisted monitoring of warfarin therapy. J Clin Pharm Ther, 2005. 30 (4): p. 345-53.
52. Jackson, S.L., G.M. Peterson, and L.R. Bereznicki, Clopidogrel-aspirin combination for atrial fibrillation: CLAAF is not CLEAR. Am Heart J, 2005. 149 (1): p. e3; author reply e4.
53. Jackson SL, Warfarin. Australian Pharmacist, 2005. 24 (4): p. 302-307.
54. Jackson SL, Bereznicki LR, and Peterson GM, An important role for community pharmacy in reducing evidence gaps. Australian Pharmacist, 2005. 24 (7): p. 558.
55. Jackson SL, Bereznicki LR, and Peterson GM, Under-use of B-Blockers. Australian Pharmacist, 2005. 24 (9): p. 691.
56. Jackson SL, Peterson GM, and Bereznicki LR, Accuracy, clinical usefulness and perceptions of community phamracy based INR monitoring in rural Australia. Journal of Clinical Pharmacy and Therapeutics, 2005. 30 : p. 345-353.
57. Jackson SL, Bereznicki LR, and Peterson GM, Closing the gap between evidence and practice; Key role for hospital pharmacists. J Pharm Pract Res, 2005. 35 : p. 173-175.
58. Jackson SL, Bereznicki LR, and Peterson GM, Pharmacists bridging the gap between evidence and practice. Under-use of ACE-inhibitors and B-Blocker hterapies in congestive cardiac failure. Aust Pharmacist, 2005. 24 : p. 936.
59. Jackson SL, Bereznicki LR, and Peterson GM, An important role for communtiy pharmacy in reducing evidence gaps. Aust Pharmacist, 2005. 24 (7): p. 558.
60. Jackson SL, et al. Uptake and impact of 4 models of the home medication review process for high risk patients after hospital discharge: The Med eSupport Trial . in Society of Hospital Pharmacists of Australia, Federal Conference . 2005. Brisbane, Queensland.
61. Jackson SL, et al. Review of the initiation of warfarin in Tasmania . in Society of Hospital Pharmacists of Australia, Tasmania Branch Annual Conference . 2005. St Helens, Tasmania.
62. Jackson SL, COPD: guidelines for management. Aust Pharmacist, 2005. 24 (6): p. 462-466.
63. Jacobson, G.A., et al., Selenoprotein P analysis in human plasma: a discrepancy between HPLC fractionation of human plasma with heparin-affinity chromatography and SDS-PAGE with immunoblot analysis. Biol Trace Elem Res, 2005. 107 (3): p. 213-20.
64. McShane RE, et al. Resolution of drug related problems and unplanned hospital readmission rates in the Med eSupport trial . in Society of Hospital Pharmacists of Australia, Federal Conference . 2005. Brisbane, Queensland.
65. Naunton M, et al., The enigma of aspirin in primary prevention. Australian Pharmacist, 2005. 24 (9): p. 718-722.
66. Naunton M and Jackson SL, Digoxin/Diamox (letter). Australian Pharmacist, 2005. 24 (3): p. 183.
67. Naunton M and Peterson GM, Newly diagnosed asthma in a child. Aust Pharmacist, 2005. 24 : p. 448-451.
68. Naunton M and Peterson GM, The role of community pharmacy in screening for osteoporosis. Aust Pharmacist, 2005. 24 : p. 484-487.
69. Naunton M and Peterson GM, The "D"ilemma - ensuring the elderly fall in love with vitamin D. Aust Pharmacist, 2005. 24 : p. 563-566.
70. Naunton M and Peterson GM, Alzheimer's Disease: Do not forget the evidence. Aust Pharmacist, 2005. 24 : p. 878-881.
71. Peterson, G.M. and M. Naunton, Valproate: a simple chemical with so much to offer. J Clin Pharm Ther, 2005. 30 (5): p. 417-21.
72. Peterson, G.M., Selecting nonprescription analgesics. Am J Ther, 2005. 12 (1): p. 67-79.
73. Peterson, G.N., et al., Management of the difficult airway: a closed claims analysis. Anesthesiology, 2005. 103 (1): p. 33-9.
74. Peterson GM and Jackson SL, Electrolyte issues in the elderly. Sodium: source of confusion? Australian Pharmacist, 2005. 24 (3): p. 202-204.
75. Peterson GM and Jackson SL, Promotion of HMRs: the consultant pharmacist's critical role. Aust J Pharm, 2005. 86 : p. 246-247.
76. Peterson GM, Electrolyte issues in the elderly. Potassium: the good and the bad. Aust Pharmacist, 2005. 24 : p. 27-29.
77. Peterson GM, Medication usage in the elderly: no signs of improvement. NZ Pharm, 2005. 25 (5): p. 25-29.
78. Peterson GM, DVD takes the country to the student , in Aust Pharmacist . 2005. p. 10.
79. Peterson GM and Bereznicki LR, Protection of the public or protection of the pharmaceutical industry? (letter). Australian Prescriber, 2005. 28 (4): p. 86.
80. Reeve JF, et al. Use of a decision support prompt in pharmacy dispensing software to promote clinical interventions by pharmacists . in Joint meeting of ASCEPT and APSA . 2005. Melbourne, Australia.
81. Tenni PC, PROMISe II begins , in Aust Pharmacist . 2005. p. 11.
82. Tenni PC, Applying the evidence: Being appropriate, not dogmatic. Aust Pharmacist, 2005. 24 (6): p. 452-453.
83. Tenni PC, Postural hypotension: a common problem in the elderly. Aust Pharmacist, 2005. 24 (4): p. 292-293.
84. Tenni PC, Now hear this...another problem with quinine. Aust Pharmacist, 2005. 24 (2): p. 124-125.
85. Tenni PC, Caution with replacement of steroids in adrenal insufficiency (Addison's Disease). Aust Pharmacist, 2005. 24 (12): p. 934-935.
86. Tenni PC, Aortic stenosis no longer a contraindication to ACE inhibitors, but caution still required. Aust Pharmacist, 2005. 24 (10): p. 778-779.
87. Tenni PC, Complications of hyperparathyroidism. Aust Pharmacist, 2005. 24 (8): p. 614-615.
88. Tenni PC, et al. The economic impact of clinical interventions in Australian community pharmacy - The PROMISe Project . in Joint Meeting of ASCEPT and APSA . 2005. Melbourne, Australia.
89. Tompson AJ, et al. Medication knowledge, compliance and humanistic outcomes in the Med eSupport trial . in Society of Hospital Pharmacists of Australia, Federal Conference . 2005. Brisbane, Queensland.
90. Tompson AJ, et al. Utilisation and perceptions of a secure interactive website for patient medication histories by community pharmacists, general practitioners and patients: The Med eSupport Trial. in Society of Hospital Pharmacists of Australia, Federal Conference . 2005. Brisbane, Queensland.
91. Tompson AJ, et al. Discrepancies in medication histories utilising community pharmacy dispensing records and admission orders in newly hospitalised patients: The Med eSupport Trial . in Society of Hospital Pharmacists of Australia, Federal Conference . 2005. Brisbane, Queensland.
92. Vlassak EE, Jackson SL, and Peterson GM. Outcomes in the management of atrial fibrillation in North and South Tasmania . in Society of Hospital Pharmacists of Australia, Tasmania Branch Annual Conference . 2005. St Helens, Tasmania.
93. Bereznicki LR, et al., The risks of warfarin use in the elderly. Expert Opinion on Drug Safety, 2006. 5 (3): p. 417-431.
94. Bereznicki LR, Jackson SL, and Peterson GM, Pharmacists bridging the gap between evidence and practice. Prevention of age-related macular degeneration. Aust Pharmacist, 2006. 25 (3): p. 244,251.
95. Bereznicki LR, et al., Home-monitoring of warfarin; The ultimate strategy to improve the safety of anticoagulation. Aust Pharmacist, 2006. 25 (3): p. 246-251.
96. Bereznicki LR, Jackson SL, and Peterson G. M., Ximelagatran cost effectiveness for stroke prevention in atrial fibrillation (letter). Journal of Pharmacy Practice and Research, 2006. 36 (2): p. in press.
97. Bereznicki LR, Jackson SL, and Peterson GM, Combining aspirin and clopidogrel: when is one better than both? Australian Pharmacist, 2006. 26 (6): p. 480.
98. Bereznicki LR, et al., Accuracy and clinical utility of the CoaguChek XS portable international normalised ratio monitor in a pilot study of warfarin home-monitoring. J Clin Pathol, 2006.
99. Jackson SL, Thyroid disorders: hypothyroidism. Aust Pharmacist, 2006. 25 (3): p. 234-239.
100. Jackson SL, Bereznicki LR, and Peterson GM, Hypertension. Aust Pharmacist, 2006. 25 (2): p. 158.
101. Jackson SL, Bereznicki LR, and Peterson GM, Preventing osteoporosis-related fractures. Australian Pharmacist, 2006. 25 (4): p. 318.
102. Jackson SL, Naunton M, and Peterson GM, Essential CPE. Medication Adherence . June 2006 ed. Essential CPE. 2006: Pharmaceutical Society of Australia.
103. Jacobson GA, Narkowicz C, and Peterson GM, Plasma glutathione peroxidase by ELISA and relationship to selenium level. Clinica Chimica Acta, 2006(in press).
104. Kimber PP and Peterson GM, Telepharmacy - Enabling technology to provide quality pharmacy services in rural and remote towns. Journal of pharmacy practice and research, 2006. 36 (2): p. 1-6.
105. Naunton, M., G.M. Peterson, and G. Jones, Pharmacist-provided quantitative heel ultrasound screening for rural women at risk of osteoporosis. Ann Pharmacother, 2006. 40 (1): p. 38-44.
106. Naunton, M. and M. Duyvendak, Underuse of antiplatelets and inappropriate use. Eur J Clin Pharmacol, 2006. 62 (1): p. 81-2.
107. Naunton, M., et al., Comments on Glintborg et al.'s drug-drug interactions study (EJCP 2005; 61: 675-681). Eur J Clin Pharmacol, 2006: p. 1-2.
108. Naunton M, et al., Practice patterns in osteoporosis prevention in patients on glucocorticoids. Osteoporos Int, 2006. in press .
109. Naunton M and Jackson SL, Fosamax, Celebrex or Panamax (letter). Aust Pharmacist, 2006. 25 (1): p. 6.
110. Naunton M and Peterson GM, Vertebral fractures. Australian Pharmacist, 2006. 25 (4): p. 296-301.
111. Naunton M, Osteoporosis (Continuing Education from the Pharmaceutical Society of Australia). 2006. March .
112. Naunton M and Peterson GM, Serotonin toxicity in the elderly. Australian Pharmacist, 2006. 25 (5): p. 406-9.
113. Peterson GM, Naunton M, and Jackson SL, Analgesia in the elderly: should not be a painful experience. Aust Pharmacist, 2006. 25 (1): p. 52-55,60.
114. Peterson GM, Why ibuprofen should be re-scheduled to pharmacy only. Aust J Pharm, 2006. 87 : p. 22-23.
115. Peterson GM, Jackson SL, and Bereznicki LR, Evidence-practice gaps (letter). Aust Pharmacist, 2006. 25 (1): p. 6.
116. Tenni PC, Post Hoc Ergo Propter Hoc: does digoxin increase survival in heart failure patients? Aust Pharmacist, 2006. 25 (2): p. 138-139.
117. Tenni PC, Antipsychotics in elderly patients with dementia. Australian Pharmacist, 2006. 25 (4): p. 306-7.
118. Tenni PC, Atrial Fibrillation with a slow heart rate. Australian Pharmacist, 2006. 25 (6): p. 462-463.
119. Tenni PC, Not so idiopathic thrombocytopaenic purpura. Australian Pharmacist, 2006. 25 (9): p. 704
120. Tenni PC, Osteoporosis prevention for very old patients. Australian Pharmacist, 2006. 25 (10): p. 782
121. Tenni PC, Hyperuricaemia. Australian Pharmacist, 2006. 25 (12): p. 942-945.
122. Peterson GM and Jackson SL, Patient compliance in the Prevention and Treatment of cardiovascular disease , in Patient Compliance; sweetening the pill , Davies M and K. F, Editors. 2006, Gower Publishing
123. Peterson GM, Rosuvastatin: 'me-too' drug or genuine advance in the management of cardiovascular disease? Australian Pharmacist, 2006. 25 (12): p. education extra 1-7.
124. Peterson GM, Bereznicki LR, and Jackson SL, NSAIDS, the authors respond (letter). Australian Pharmacist, 2006. 25 (12): p. 906.
125. Peterson GM, Jackson SL, and Naunton M, Home medicines review in the elderly: most effective if performed and reported in a timely manner. Australian Pharmacist, 2006. 25 (11): p. 860-863.
126. Peterson GM, et al., Delirious dangers of the deadly nightshade - beware of anticholinergics in the elderly. Australian Pharmacist, 2006. 25 (11): p. 882-884.
127. Peterson GM, Jackson SL, and Tompson AJ, Discharge Medication (letter). Australian Prescriber, 2006. 29 (5): p. 133.
128. Peterson GM, Laboratory monitoring of drug therapy in the elderly: often inadequate. Australian Pharmacist, 2006. 25 (9): p. 690-693.
129. Peterson GM, Jackson SL, and Bereznicki LR, Evidence-practice gaps (letter). Aust Pharmacist, 2006. 25 (1): p. 6.
130. Naunton M, Peterson GM, and Jones G, Under-use of bisphosphonates in rural elderly women who have sustained fractures (letter). Aust J Rural Health, 2006. 14 (286).
131. Naunton M, Peterson GM, and Jackson SL, Constipation in the elderly: can we achieve movement with evidence-based recommendations? Australian Pharmacist, 2006. 25 (7): p. 564-569.
132. J ackson SL and Peterson GM, Health screening in community pharmacy: an update. Australian Pharmacist, 2006. 25 (11): p. 846-851.
133. Jackson SL, Tenni PC, and Naunton M, Collaborative RMMRs in Aged Care Facilities. Australian Pharmacist, 2006. 25 (10): p. 758-759
134. Jackson SL, A user's guide to the APF 20. Australian Pharmacist, 2006. 25 (8): p. 647.
135. Bereznicki LR, Jackson SL, and Peterson GM, Which is the safest NSAID for patients at elevated cardiovascular risk? Australian Pharmacist, 2006. 25 (11): p. 853.
136. Bereznicki LR, Jackson SL, and Peterson GM, Encouraging periconceptional use of folic acid supplements. Australian Pharmacist, 2006. 25 (9): p. 706.
137. Bereznicki LR, Jackson SL, and Peterson GM, Comment: Increased sensitivity to warfarin after heart valve replacement (letter). Ann Pharmacother, 2006. 40 (July/August): p. 1476-1477.
138. Bereznicki LR, Jackson SL, and Peterson GM, Encouraging the rational use of probiotics in combination with antibiotics - what are we trying to prevent? Australian Pharmacist, 2007. 26 (1): p. 26.
139. Peterson GM, Fountain of youth: can we prevent ageing? Australian Pharmacist, 2007. 26 (1): p. 28-31.
140. Bindoff IK, Tenni PC, Peterson GM, Kang BH, JAckson SL, Development of an intelligent decision support system for medication review . J Clin Pharm Ther, 2007. 32 , p 81-88
UMORE homepage
